{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T14:52:13Z","timestamp":1784299933583,"version":"3.55.0"},"reference-count":77,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T00:00:00Z","timestamp":1625616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Buprenorphine (BUP) is a commonly prescribed medication for the treatment of opioid use disorder (OUD). As prescriptions increase in North Carolina, BUP is more frequently encountered statewide in routine postmortem casework. Between 2010 and 2018, there were 131 select cases investigated by the Office of the Chief Medical Examiner where BUP was detected in peripheral blood and considered a primary cause of death (COD), with no other opioids present and no other non-opioid substances found in the lethal range. The decedents ranged in age from 14 to 64\u2009years, with 67% male. The mean\/median peripheral blood concentrations were 4.1\/2.1\u2009ng\/mL for BUP and 7.8\/3.4\u2009ng\/mL for its metabolite, norbuprenorphine. These postmortem blood concentrations overlap antemortem therapeutic concentrations in plasma reported in the literature for opioid-dependent subjects receiving sublingual maintenance therapy. The pathologist considered scene findings, prescription history, autopsy findings, toxicological analysis and decedent behavior prior to death to conclude a drug-related COD. Many of the deaths were complicated by the presence of other central nervous system depressants along with contributory underlying cardiovascular and respiratory disease. The three most prevalent additive substances were alprazolam, ethanol and gabapentin, found in 67, 36 and 32 cases out of 131, respectively. Interpreting BUP involvement in a death is complex, and instances may be underestimated in epidemiological data because of the lack of a defined toxic or lethal range in postmortem blood along with its good safety profile. As expansion of access to OUD treatment becomes a priority, awareness of the challenges of postmortem interpretation is needed as increased use and diversion of BUP are inevitable.<\/jats:p>","DOI":"10.1093\/jat\/bkab073","type":"journal-article","created":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T19:12:35Z","timestamp":1624043555000},"page":"780-791","source":"Crossref","is-referenced-by-count":14,"title":["Buprenorphine-Related Deaths in North Carolina from 2010 to 2018"],"prefix":"10.1093","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0900-457X","authenticated-orcid":false,"given":"Sandra C","family":"Bishop-Freeman","sequence":"first","affiliation":[{"name":"Office of the Chief Medical Examiner, 4312 District Dr, Raleigh, NC 27607, USA"},{"name":"UNC Department of Pathology and Laboratory Medicine, 160 Medical Dr., Chapel Hill, NC 27559, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura W","family":"Friederich","sequence":"additional","affiliation":[{"name":"Office of the Chief Medical Examiner, 4312 District Dr, Raleigh, NC 27607, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S","family":"Feaster","sequence":"additional","affiliation":[{"name":"Office of the Chief Medical Examiner, 4312 District Dr, Raleigh, NC 27607, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason S","family":"Hudson","sequence":"additional","affiliation":[{"name":"Office of the Chief Medical Examiner, 4312 District Dr, Raleigh, NC 27607, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,7,7]]},"reference":[{"key":"2021091706013621200_R1","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1016\/j.mayocp.2019.03.029","article-title":"Medication-assisted treatment for opioid-use disorder","volume":"94","author":"Oesterle","year":"2019","journal-title":"Mayo Clinic Proceedings"},{"key":"2021091706013621200_R2","article-title":"U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration","author":"Buprenorphine","year":"2021"},{"key":"2021091706013621200_R3","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/clpt.1994.71","article-title":"Clinical pharmacology of buprenorphine: ceiling effects at high doses","volume":"55","author":"Walsh","year":"1994","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"2021091706013621200_R4","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1093\/bja\/ael051","article-title":"Buprenorphine induces ceiling in respiratory depression but not in analgesia","volume":"96","author":"Dahan","year":"2006","journal-title":"British Journal of Anaesthesia"},{"key":"2021091706013621200_R5","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1097\/01.jcp.0000138766.15858.c6","article-title":"Effects of high-dose intravenous buprenorphine in experienced opioid abusers","volume":"24","author":"Umbricht","year":"2004","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"2021091706013621200_R6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1080\/00325481.2017.1270156","article-title":"Effects of buprenorphine on QT intervals in healthy subjects: results of 2 randomized positive- and placebo-controlled trials","volume":"129","author":"Harris","year":"2017","journal-title":"Postgraduate Medicine"},{"key":"2021091706013621200_R7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/ADM.0000000000000176","article-title":"Presence or absence of QTc prolongation in buprenorphine-naloxone among youth with opioid dependence","volume":"10","author":"Poole","year":"2016","journal-title":"Journal of Addiction Medicine"},{"key":"2021091706013621200_R8","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2165\/00003088-200544070-00001","article-title":"Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence","volume":"44","author":"Elkader","year":"2005","journal-title":"Clinical Pharmacokinetics"},{"key":"2021091706013621200_R9","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1124\/jpet.102.038240","article-title":"Influence of opioid agonists on cardiac human ether-a-go-go -related Gene K + currents","volume":"303","author":"Katchman","year":"2002","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"2021091706013621200_R10","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1093\/jat\/22.6.430","article-title":"Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities","volume":"22","author":"Tracqui","year":"1998","journal-title":"Journal of Analytical Toxicology"},{"key":"2021091706013621200_R11","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.forsciint.2018.08.010","article-title":"High buprenorphine-related mortality is persistent in Finland","volume":"291","author":"Kriikku","year":"2018","journal-title":"Forensic Science International"},{"key":"2021091706013621200_R12","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108345","article-title":"Concomitant drugs with buprenorphine user deaths","volume":"218","author":"Mariottini","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"key":"2021091706013621200_R13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/ADM.0000000000000457","article-title":"Buprenorphine pharmacology review: update on transmucosal and long-acting formulations","volume":"13","author":"Coe","year":"2019","journal-title":"Journal of Addiction Medicine"},{"key":"2021091706013621200_R14","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.drugalcdep.2012.11.014","article-title":"Intravenous buprenorphine and norbuprenorphine pharmacokinetics in humans","volume":"131","author":"Huestis","year":"2013","journal-title":"Drug and Alcohol Dependence"},{"key":"2021091706013621200_R15","first-page":"115","article-title":"Metabolism and disposition of prescription opioids: a review","volume":"27","author":"DePriest","year":"2015","journal-title":"Forensic Science Review"},{"key":"2021091706013621200_R16","doi-asserted-by":"publisher","first-page":"859","DOI":"10.2147\/JPR.S85951","article-title":"Buprenorphine - an attractive opioid with underutilized potential in treatment of chronic pain","volume":"8","author":"Khanna","year":"2015","journal-title":"Journal of Pain Research"},{"key":"2021091706013621200_R17","first-page":"688","article-title":"Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist","volume":"297","author":"Huang","year":"2001","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"2021091706013621200_R18","doi-asserted-by":"publisher","first-page":"S269","DOI":"10.1111\/1556-4029.12621","article-title":"An unusual case of death probably triggered by the association of buprenorphine at therapeutic dose with ethanol and benzodiazepines and with very low norbuprenorphine level","volume":"60","author":"Bardy","year":"2015","journal-title":"Journal of Forensic Sciences"},{"key":"2021091706013621200_R19","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1097\/ALN.0b013e318238fea0","article-title":"Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active","volume":"115","author":"Brown","year":"2011","journal-title":"Anesthesiology"},{"key":"2021091706013621200_R20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2014.07.035","article-title":"Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy","volume":"144","author":"Greenwald","year":"2014","journal-title":"Drug and Alcohol Dependence"},{"key":"2021091706013621200_R21","volume-title":"Handbook of Forensic Toxicology for Medical Examiners","author":"Molina","year":"2019","edition":"2nd"},{"key":"2021091706013621200_R22","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2165\/00003088-200443050-00005","article-title":"Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality","volume":"43","author":"Harris","year":"2004","journal-title":"Clinical Pharmacokinetics"},{"key":"2021091706013621200_R23","article-title":"NC Medicaid Office-Based Opioid Treatment: Use of Buprenorphine and Buprenorphine-Naloxone","year":"2018"},{"key":"2021091706013621200_R24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.forsciint.2013.06.017","article-title":"Parenteral buprenorphine\u2013naloxone abuse is a major cause of fatal buprenorphine-related poisoning","volume":"232","author":"H\u00e4kkinen","year":"2013","journal-title":"Forensic Science International"},{"key":"2021091706013621200_R25","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.drugalcdep.2015.08.007","article-title":"Buprenorphine infrequently found in fatal overdose in New York City","volume":"155","author":"Paone","year":"2015","journal-title":"Drug and Alcohol Dependence"},{"key":"2021091706013621200_R26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s13181-020-00795-3","article-title":"Opioid overdose deaths with buprenorphine detected in postmortem toxicology: a retrospective analysis","volume":"17","author":"Wightman","year":"2021","journal-title":"Journal of Medical Toxicology"},{"key":"2021091706013621200_R27","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S0379-0738(01)00454-6","article-title":"Deaths involving buprenorphine: a compendium of French cases","volume":"121","author":"Kintz","year":"2001","journal-title":"Forensic Science International"},{"key":"2021091706013621200_R28","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.forsciint.2006.03.037","article-title":"A survey of buprenorphine related deaths in Singapore","volume":"162","author":"Lai","year":"2006","journal-title":"Forensic Science International"},{"key":"2021091706013621200_R29","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1034\/j.1399-6576.2003.00201.x","article-title":"Serious overdoses involving buprenorphine in Helsinki","volume":"47","author":"Boyd","year":"2003","journal-title":"Acta Anaesthesiologica Scandinavica"},{"key":"2021091706013621200_R30","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108360","article-title":"Characteristics and circumstances of death related to buprenorphine toxicity in Australia","volume":"218","author":"Darke","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"key":"2021091706013621200_R31","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1046\/j.1360-0443.1999.9479612.x","article-title":"Mechanisms of fatal opioid overdose","volume":"94","author":"White","year":"1999","journal-title":"Addiction (Abingdon, England)"},{"key":"2021091706013621200_R32","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1093\/jat\/bkz068","article-title":"Bupenorphine in Wisconsin drivers: concerns for impairment?","volume":"43","author":"Edwards","year":"2019","journal-title":"Journal of Analytical Toxicology"},{"key":"2021091706013621200_R33","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1080\/15563650.2020.1814318","article-title":"Respiratory depression following medications for opioid use disorder (MOUD)-approved buprenorphine product oral exposures; National Poison Database System 2003\u20132019","volume":"59","author":"Darracq","year":"2020","journal-title":"Clinical Toxicology"},{"key":"2021091706013621200_R34","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1111\/j.1360-0443.2004.00790.x","article-title":"A critical review of the causes of death among post-mortem toxicological investigations: analysis of 34 buprenorphine-associated and 35 methadone-associated deaths","volume":"99","author":"Pirnay","year":"2004","journal-title":"Addiction"},{"key":"2021091706013621200_R35","volume-title":"Disposition of Toxic Drugs and Chemicals in Man","author":"Baselt","year":"2014","edition":"10th"},{"key":"2021091706013621200_R36","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01210","article-title":"Postmortem toxicology of new synthetic opioids","volume":"9","author":"Concheiro","year":"2018","journal-title":"Frontiers in Pharmacology"},{"key":"2021091706013621200_R37","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1016\/j.forsciint.2010.05.015","article-title":"Fatal poisoning due to snorting buprenorphine and alcohol consumption","volume":"204","author":"Ferrant","year":"2011","journal-title":"Forensic Science International"},{"key":"2021091706013621200_R38","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bkz115","article-title":"ANSI\/ASB standard 036 for method validation in forensic toxicology has replaced SWGTOX\u2019s version","volume":"44","author":"LeBeau","year":"2020","journal-title":"Journal of Analytical Toxicology"},{"key":"2021091706013621200_R39","article-title":"NCMS Foundation Launches Project OBOT","author":"Ellis","year":"2018"},{"key":"2021091706013621200_R40","first-page":"372","volume-title":"Int J Legal Med","author":"Beike","year":"2002"},{"key":"2021091706013621200_R41","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00414-010-0449-1","article-title":"Buprenorphine-related deaths: unusual forensic situations","volume":"124","author":"Pelissier-Alicot","year":"2010","journal-title":"International Journal of Legal Medicine"},{"key":"2021091706013621200_R42","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1093\/toxsci\/kfw221","article-title":"Editor\u2019s highlight: neurorespiratory effects of buprenorphine and ethanol in combination: a mechanistic study of drug\u2013drug interactions in the rat","volume":"155","author":"Cohier","year":"2017","journal-title":"Toxicological Sciences"},{"key":"2021091706013621200_R43","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1111\/j.1360-0443.2011.03424.x","article-title":"The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine\/naloxone tablets in opioid abusers: Intranasal buprenorphine in humans","volume":"106","author":"Middleton","year":"2011","journal-title":"Addiction"},{"key":"2021091706013621200_R44","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.forsciint.2012.03.016","article-title":"Toxicological and pathological findings in a series of buprenorphine related deaths. Possible risk factors for fatal outcome","volume":"220","author":"Seld\u00e9n","year":"2012","journal-title":"Forensic Science International"},{"key":"2021091706013621200_R45","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00228-011-1122-4","article-title":"Benzodiazepines and alcohol are associated with cases of fatal buprenorphine poisoning","volume":"68","author":"H\u00e4kkinen","year":"2012","journal-title":"European Journal of Clinical Pharmacology"},{"key":"2021091706013621200_R46","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.resp.2005.03.009","article-title":"Role of NMDA receptors in development of respiratory control","volume":"149","author":"Waters","year":"2005","journal-title":"Respiratory Physiology and Neurobiology"},{"key":"2021091706013621200_R47","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1093\/bja\/aen094","article-title":"Opioids and the control of respiration","volume":"100","author":"Pattinson","year":"2008","journal-title":"British Journal of Anaesthesia"},{"key":"2021091706013621200_R48","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.drugalcdep.2012.07.004","article-title":"Polydrug abuse: a review of opioid and benzodiazepine combination use","volume":"125","author":"Jones","year":"2012","journal-title":"Drug and Alcohol Dependence"},{"key":"2021091706013621200_R49","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/0897190013515001","article-title":"Benzodiazepines: a major component in unintentional prescription drug overdoses with opioid analgesics","volume":"27","author":"Jann","year":"2014","journal-title":"Journal of Pharmacy Practice"},{"key":"2021091706013621200_R50","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1254\/jphs.08249FP","article-title":"Comparison of five benzodiazepine-receptor agonists on buprenorphine-induced mu-opioid receptor regulation","volume":"110","author":"Poisnel","year":"2009","journal-title":"Journal of Pharmacological Sciences"},{"key":"2021091706013621200_R51","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2165\/00139709-200625020-00002","article-title":"Does high-dose buprenorphine cause respiratory depression? Possible mechanisms and therapeutic consequences","volume":"25","author":"Megarbane","year":"2006","journal-title":"Toxicological Reviews"},{"key":"2021091706013621200_R52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1176\/appi.ajp.2020.20081174","article-title":"Association between benzodiazepine or Z-drug prescriptions and drug-related poisonings among patients receiving buprenorphine maintenance: a case-crossover analysis","author":"Xu","year":"2021","journal-title":"American Journal of Psychiatry, AJP in Advance"},{"key":"2021091706013621200_R53","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.drugalcdep.2005.01.004","article-title":"The effect of buprenorphine and benzodiazepines on respiration in the rat","volume":"79","author":"Nielsen","year":"2005","journal-title":"Drug and Alcohol Dependence"},{"key":"2021091706013621200_R54","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00228-004-0856-7","article-title":"Effect of benzodiazepines on the metabolism of buprenorphine in human liver microsomes","volume":"60","author":"Chang","year":"2005","journal-title":"European Journal of Clinical Pharmacology"},{"key":"2021091706013621200_R55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002396","article-title":"Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case-control study","volume":"14","author":"Gomes","year":"2017","journal-title":"PLoS Medicine"},{"key":"2021091706013621200_R56","doi-asserted-by":"publisher","first-page":"97","DOI":"10.5812\/atr.11011","article-title":"Gabapentin and diclofenac reduce opioid consumption in patients undergoing tonsillectomy: a result of altered CNS drug delivery?","volume":"2","author":"Ronaldson","year":"2013","journal-title":"Archives of Trauma Research"},{"key":"2021091706013621200_R57","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2014.13111526","article-title":"Potentiation of the effect of buprenorphine\/naloxone with gabapentin or quetiapine","volume":"171","author":"Reeves","year":"2014","journal-title":"The American Journal of Psychiatry"},{"key":"2021091706013621200_R58","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-019-01091-0","article-title":"Buprenorphine\u2013cannabis interaction in patients undergoing opioid maintenance therapy","author":"Vierke","year":"2020","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"key":"2021091706013621200_R59","doi-asserted-by":"publisher","first-page":"310","DOI":"10.2174\/138920008784220664","article-title":"Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4","volume":"9","author":"Zhou","year":"2008","journal-title":"Current Drug Metabolism"},{"key":"2021091706013621200_R60","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1023\/A:1018877803319","article-title":"Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein","volume":"16","author":"Kim","year":"1999","journal-title":"Pharmaceutical Research"},{"key":"2021091706013621200_R61","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1097\/CCM.0b013e318265680a","article-title":"Respiratory toxicity of buprenorphine results from the blockage of P-glycoprotein-mediated efflux of norbuprenorphine at the blood-brain barrier in mice","volume":"40","author":"Alhaddad","year":"2012","journal-title":"Critical Care Medicine"},{"key":"2021091706013621200_R62","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1124\/jpet.106.115972","article-title":"Pharmacokinetic-pharmacodynamic modeling of the respiratory depressant effect of norbuprenorphine in rats","volume":"321","author":"Yassen","year":"2007","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"2021091706013621200_R63","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1124\/jpet.112.193433","article-title":"P-glycoprotein is a major determinant of norbuprenorphine brain exposure and antinociception","volume":"343","author":"Brown","year":"2012","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"2021091706013621200_R64","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.phrs.2017.01.018","article-title":"P-gp\/ABCB1 exerts differential impacts on brain and fetal exposure to norbuprenorphine","volume":"119","author":"Liao","year":"2017","journal-title":"Pharmacological Research"},{"key":"2021091706013621200_R65","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1017\/S1461145709990848","article-title":"Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)","volume":"13","author":"Tournier","year":"2010","journal-title":"The International Journal of Neuropsychopharmacology"},{"key":"2021091706013621200_R66","doi-asserted-by":"publisher","first-page":"81","DOI":"10.5414\/CP203118","article-title":"Norbuprenorphine and respiratory depression: exploratory analyses with new lyophilized buprenorphine and sublingual buprenorphine","volume":"56","author":"Strang","year":"2018","journal-title":"International Journal of Clinical Pharmacology and Therapeutics"},{"key":"2021091706013621200_R67","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S1754-3207(08)60017-6","article-title":"Basic pharmacology of buprenorphine","volume":"1","author":"Ohtani","year":"2007","journal-title":"European Journal of Pain Supplements"},{"key":"2021091706013621200_R68","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.2460\/ajvr.68.10.1106","article-title":"Assessment of antiepileptic drugs as substrates for canine P-glycoprotein","volume":"68","author":"West","year":"2007","journal-title":"American Journal of Veterinary Research"},{"key":"2021091706013621200_R69","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1124\/jpet.102.046532","article-title":"Inhibition of P-glycoprotein by newer antidepressants","volume":"305","author":"Weiss","year":"2003","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"2021091706013621200_R70","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00210-018-01605-y","article-title":"The inhibitory effects of mitragynine on P-glycoprotein in vitro","volume":"392","author":"Rusli","year":"2019","journal-title":"Naunyn-Schmiedeberg\u2019s Archives of Pharmacology"},{"key":"2021091706013621200_R71","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1124\/jpet.105.098541","article-title":"Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana","volume":"317","author":"Zhu","year":"2006","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"2021091706013621200_R72","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.jsat.2012.08.010","article-title":"Prescription opioid abuse, chronic pain, and primary care: a co-occurring disorders clinic in the chronic disease model","volume":"43","author":"Pade","year":"2012","journal-title":"Journal of Substance Abuse Treatment"},{"key":"2021091706013621200_R73","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1111\/add.13013","article-title":"Arrhythmia associated with buprenorphine and methadone reported to the food and drug administration: arrhythmia: buprenorphine versus methadone","volume":"110","author":"Kao","year":"2015","journal-title":"Addiction"},{"key":"2021091706013621200_R74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0241362","article-title":"Mechanisms of QT prolongation by buprenorphine cannot be explained by direct hERG channel block","volume":"15","author":"Tran","year":"2020","journal-title":"PLoS One"},{"key":"2021091706013621200_R75","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-130-6-199903160-00011","article-title":"Myocardial infarction associated with buprenorphine","volume":"130","author":"Cracowski","year":"1999","journal-title":"Annals of Internal Medicine"},{"key":"2021091706013621200_R76","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1183\/09031936.00120012","article-title":"Sleep disordered breathing in patients receiving therapy with buprenorphine\/naloxone","volume":"42","author":"Farney","year":"2013","journal-title":"The European Respiratory Journal"},{"key":"2021091706013621200_R77","doi-asserted-by":"publisher","DOI":"10.7326\/L19-0145","article-title":"The next stage of buprenorphine care for opioid use disorder","volume":"170","author":"Martin","year":"2019","journal-title":"Annals of Internal Medicine"}],"container-title":["Journal of Analytical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jat\/advance-article-pdf\/doi\/10.1093\/jat\/bkab073\/38876138\/bkab073.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jat\/article-pdf\/45\/8\/780\/40397352\/bkab073.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jat\/article-pdf\/45\/8\/780\/40397352\/bkab073.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T06:14:45Z","timestamp":1631859285000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jat\/article\/45\/8\/780\/6305277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,7]]},"references-count":77,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,7,7]]},"published-print":{"date-parts":[[2021,9,17]]}},"URL":"https:\/\/doi.org\/10.1093\/jat\/bkab073","relation":{},"ISSN":["0146-4760","1945-2403"],"issn-type":[{"value":"0146-4760","type":"print"},{"value":"1945-2403","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10,1]]},"published":{"date-parts":[[2021,7,7]]}}}